TenX Keane Acquisition(TENK) - 2025 Q3 - Quarterly Results
TenX Keane AcquisitionTenX Keane Acquisition(US:TENK)2025-12-23 21:50

Exhibit 99.1 Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025 Completed $36 million in strategic financings, of which $18 million was via private placement and concurrent registered direct of ering on December 10, 2025, to strengthen cash position and support continued commercialization of LYMPHIR CRANFORD, N.J., December 23, 2025 – Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the ...